Treating tumors

PATIENTS don’t automatically have to undergo surgery to remove a tumor, defined as an abnormal overgrowth of cells in any part of the body. Instead, it can be addressed by a multidisciplinary approach, according to Cardinal Santos Medical Center (CSMC) specialists at a webinar on brain and spine tumor management in February. “We suggest the […]

Eisai to Launch Digital Too “Cogmate” in Taiwan and Hong Kong for Self-Assessment of Brain Performance (Brain Health)

TOKYO, Jan 13, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today that its Taiwanese subsidiary Eisai Taiwan Inc. and Hong Kong subsidiary Eisai (Hong Kong) Co., Ltd. have launched “CogMateTM”, a digital tool (non-medical device) for self-assessment of brain performance (brain health). In Taiwan and Hong Kong, the both subsidiaries target […]

Eisai: Introduction of Plasma-based Biomarker Screening to Facilitate Identification of Subjects for Phase 3 Ahead 3-45 Trial Presented at Clinical Trials on Alzheimer’s Disease (CTAD) Conference

TOKYO and CAMBRIDGE, Mass., Nov 12, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. and Biogen Inc. announced a presentation about exploring the use of plasma-based biomarkers in the Phase 3 AHEAD 3-45 study of lecanemab (BAN2401), an investigational anti-amyloid beta (Abeta) protofibril antibody. AHEAD 3-45 is the first preclinical Alzheimer’s disease (AD) […]

Eisai and ITO EN Enter Into Business Alliance Aiming to Support People Living with Dementia and to Prevent Dementia

TOKYO, May 31, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. and ITO EN, LTD. announced today that both parties have entered into a business alliance agreement concerning the initiatives for supporting people living with and preventing dementia with the aim of realizing a healthy and long-lived society. Through this alliance, Eisai and […]